Unicycive Therapeutics, Inc. - Common Stock (UNCY)
0.9000
+0.1456 (19.30%)
NASDAQ · Last Trade: Jun 9th, 11:37 PM EDT
Detailed Quote
Previous Close
0.7544
Open
0.7732
Bid
0.9050
Ask
0.9500
Day's Range
0.7551 - 1.100
52 Week Range
0.2020 - 1.100
Volume
21,244,730
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,289,228
Chart
About Unicycive Therapeutics, Inc. - Common Stock (UNCY)
Unicycive Therapeutics Inc is a biotechnology company focused on developing innovative therapies to address unmet medical needs, particularly in the areas of kidney diseases. The company is primarily engaged in creating novel drug candidates that enhance the management of renal conditions, aiming to improve patient outcomes through targeted treatments. By leveraging its expertise in drug development and its commitment to scientific research, Unicycive Therapeutics seeks to bring forth new solutions that can significantly impact the lives of individuals suffering from various kidney-related disorders. Read More
Unicycive Therapeutics (NASDAQ: UNCY) is at the forefront of developing cutting-edge therapies for kidney diseases. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.
LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer was recently featured on the Nasdaq Amplify Issuer Spotlight interview series. The series explores how industry leaders within small-cap community are evolving and navigating challenges in various industries.
